<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596880</url>
  </required_header>
  <id_info>
    <org_study_id>94-02-159-30278</org_study_id>
    <nct_id>NCT02596880</nct_id>
  </id_info>
  <brief_title>Sofosbuvir, Daclatasvir, Ribavirin for HCV Cirrhotics</brief_title>
  <acronym>SD100</acronym>
  <official_title>Sustained Viral Response Rate in 100 Subjects With Cirrhosis Due to Hepatitis C Treated With 12 Weeks of Sofosbuvir, Daclatasvir and Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will treat 100 patients with cirrhosis due to hepatitis C with sofosbuvir
      400 mg daily, daclatasvir 60 mg daily and weight-based ribavirin (1000 mg/d if &lt;75 kg, 1200
      mg/d if &gt;75 kg, divided in two daily doses) for 12 weeks and calculate the sustained viral
      response rate at 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhosis due to Hepatitis C presents a rather difficult treatment problem as many cannot
      tolerate interferon, the previous standard of treatment. The new direct acting antivirals
      have provided these patients with a new hope. One such combination is sofosbuvir (SOF) 400
      mg and daclatasvir (DCV) 60 mg given once daily with or without weight-based ribavirin (RBV)
      for 12 or 24 weeks. The current recommendation for cirrhotics is SOF/DCV/RBV for 24 weeks
      but that recommendation is based on the lack of data for shorter periods. In order to
      evaluate the response rate to the combination of SOF/DCV/RBV the investigators decided to
      treat 100 HCV cirrhotics with this combination for 12 weeks. Subjects include genotype 1 and
      3 patients, the prevalent genotypes in Iran. Patients with MELD &gt; 20 are excluded. The
      investigators will calculate the sustained viral response rate at 12 weeks (SVR12).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The sustained viral response rate</measure>
    <time_frame>week 24 (12 weeks after end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Qualitative HCV RNA PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug events</measure>
    <time_frame>week 2, 4, 8, 12, 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive sofosbuvir, daclatasvir and ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>400 mg, included in a combination pill (SoDac) with 60 mg daclatasvir</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>SoDac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>60 mg, included in a combination pill (SoDac) with 400 mg sofosbuvir</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>SoDac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1000 mg/day if &lt;75 kg, 1200 mg/day for &gt;75 kg. Divided into two daily doses</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>RBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive qualitative HCV RNA test on two occasions at least 6 months apart

          -  Cirrhosis proven by either of: 1. Liver biopsy, 2. Liver elasticity &gt; 12 KPa, 3.
             Clinical certainty (ascites, splenomegaly, small liver, low albumin, low platelet)

        Exclusion Criteria:

          -  Renal failure (eGFR &lt; 30 cc/min),

          -  MELD score &gt; 20,

          -  Child's C (CTP score &gt; 12),

          -  Heart rate &lt; 50/min,

          -  Taking amiodarone
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Malekzadeh, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahin Merat, M.D.</last_name>
    <phone>+98 917 117 3966</phone>
    <email>merat@tums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hossein Poustchi, M.D.</last_name>
    <phone>+98 912 218 7385</phone>
    <email>h.poustchi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shariati Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14117</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir-Houshang Sharifi, M.D.</last_name>
      <phone>+98 21 8241 5105</phone>
      <email>sharifi@ddrc.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Shahin Merat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hossein Poustchi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir-Houshang Sharifi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arghavan Haj-Sheykholeslami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramyar Golzari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 9, 2015</lastchanged_date>
  <firstreceived_date>November 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shahin Merat</investigator_full_name>
    <investigator_title>Professor of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Daclatasvir</keyword>
  <keyword>Ribavirin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
